CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 1 filers reported holding CLOVIS ONCOLOGY INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $75,000 | -93.5% | 15,685 | -60.2% | 0.00% | -100.0% |
| Q3 2018 | $1,157,000 | -35.4% | 39,393 | 0.0% | 0.00% | -50.0% |
| Q2 2018 | $1,791,000 | -19.9% | 39,393 | -7.0% | 0.00% | 0.0% |
| Q1 2018 | $2,236,000 | -39.7% | 42,353 | -22.3% | 0.00% | -50.0% |
| Q4 2017 | $3,708,000 | -30.1% | 54,536 | -15.3% | 0.00% | -33.3% |
| Q3 2017 | $5,303,000 | -11.1% | 64,350 | +1.0% | 0.01% | -25.0% |
| Q2 2017 | $5,965,000 | +64.4% | 63,709 | +11.8% | 0.01% | +60.0% |
| Q1 2017 | $3,628,000 | +497.7% | 56,982 | +228.5% | 0.01% | +400.0% |
| Q4 2015 | $607,000 | -4.6% | 17,345 | +150.7% | 0.00% | 0.0% |
| Q3 2015 | $636,000 | -31.9% | 6,920 | -34.9% | 0.00% | -50.0% |
| Q2 2015 | $934,000 | +96.6% | 10,625 | -7.3% | 0.00% | +100.0% |
| Q2 2014 | $475,000 | -79.2% | 11,466 | -65.2% | 0.00% | -85.7% |
| Q1 2014 | $2,284,000 | +39.5% | 32,966 | +21.4% | 0.01% | +40.0% |
| Q4 2013 | $1,637,000 | +1.1% | 27,166 | +2.0% | 0.01% | -16.7% |
| Q3 2013 | $1,619,000 | -79.0% | 26,637 | -76.8% | 0.01% | -77.8% |
| Q2 2013 | $7,697,000 | – | 114,913 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,997,826 | $10,834,000 | 0.69% |
| Ikarian Capital, LLC | 1,112,669 | $3,016,000 | 0.45% |
| Versant Venture Management, LLC | 101,855 | $276,000 | 0.15% |
| Virtus ETF Advisers LLC | 60,836 | $165,000 | 0.06% |
| EMFO, LLC | 21,500 | $58,000 | 0.05% |
| QVT Financial LP | 505,000 | $1,369,000 | 0.05% |
| QVT Financial LP | 505,000 | $1,369,000 | 0.05% |
| PINNACLE ASSOCIATES LTD | 706,336 | $1,914,000 | 0.03% |
| XTX Topco Ltd | 20,920 | $57,000 | 0.03% |
| State of Wyoming | 25,419 | $69,000 | 0.03% |